BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals announced a strategic restructuring plan to discontinue its internal discovery programs and close its Birmingham, Alabama facility by the end of 2026. This move is part of an evolution to strengthen its rare disease pipeline through external innovation, leading to a reduction in its 2026 non-GAAP operating expense guidance to $420-$440 million from $450-$470 million. The company also reaffirmed its 2026 revenue guidance and provided updates on its clinical pipeline, including the completion of navenibart's Phase 3 enrollment and resolution of an ORLADEYO manufacturing delay.

BioCryst Pharmaceuticals announced a strategic shift to prioritize external innovation, discontinuing internal discovery programs and closing its Birmingham Discovery Center by the end of 2026. This restructuring is expected to improve efficiency and lower costs, leading to an updated 2026 non-GAAP operating expense guidance of $420-$440 million, down from $450-$470 million. The company reaffirmed its 2026 revenue guidance and provided positive updates on its clinical pipeline, including completed enrollment for navenibart's Phase 3 study and resolved manufacturing delays for ORLADEYO oral pellets.

BioCryst Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where several key proposals were approved. Stockholders voted to amend and restate the Stock Incentive Plan, increasing the number of shares available for issuance by 7,000,000. Additionally, three directors were elected, the appointment of Ernst & Young LLP as independent accountants for 2026 was ratified, and a non-binding advisory vote approved the company's executive compensation.

BioCryst Pharmaceuticals announced new clinical data and real-world evidence for ORLADEYO and new data from the Phase 1b/2 ALPHA-STAR study of investigational navenibart, both for hereditary angioedema (HAE). The data, to be presented at EAACI, reinforce the strength of BioCryst's HAE portfolio, showing consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations for ORLADEYO, and consistent attack rate reductions for navenibart across patient subgroups, supporting its Phase 3 evaluation.

BioCryst Pharmaceuticals announced that its compensation committee granted equity awards to nine newly-hired employees. These awards, totaling 33,950 stock options and 80,650 restricted stock units (RSUs), were granted on June 1, 2026, as inducements for their employment. The stock options have an exercise price of $8.57 per share and both options and RSUs vest in four equal annual installments.

BioCryst Pharmaceuticals announced it will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference. The studies highlight the significant healthcare and quality-of-life burden associated with hereditary angioedema (HAE) in pediatric patients and their caregivers, demonstrating persistent unmet needs. Findings indicate children with HAE experience greater healthcare resource utilization, including outpatient visit rates more than three times higher than controls, and caregivers spend over 20 hours weekly providing care, with greater impacts on their quality of life during frequent HAE attacks. This research reinforces the importance of optimized disease management.

BioCryst Pharmaceuticals reported a significant net loss of $721.8 million for Q1 2026, primarily due to a $697.8 million acquired in-process research and development expense related to its acquisition of Astria Therapeutics, Inc. Total revenues increased to $156.4 million from $145.5 million in the prior year. The company also secured a $400 million secured term loan during the quarter, contributing to an increase in cash and cash equivalents to $171.6 million. This led to a net loss per common share of $(2.98).

BioCryst Pharmaceuticals reported Q1 2026 financial results, highlighted by ORLADEYO net revenue of $148.3 million, an 11% increase year-over-year. The company also announced a licensing agreement with Neopharmed Gentili for exclusive European commercial rights to navenibart, receiving $70 million upfront and eligibility for up to $275 million in future milestone payments. While BioCryst recorded a GAAP operating loss of $701.6 million due to a significant non-cash R&D expense from the Astria acquisition, its non-GAAP operating profit was $54.2 million. The company maintained its full-year 2026 revenue and non-GAAP operating expense guidance, reflecting continued strong execution and pipeline progress.

BioCryst Pharmaceuticals announced that its compensation committee granted restricted stock units (RSUs) covering an aggregate of 61,750 shares of common stock to six newly-hired employees. These RSUs, granted on May 1, 2026, serve as material inducements for their employment. The grants vest in four equal annual installments, beginning on the one-year anniversary of the grant date, contingent on continued service, and comply with Nasdaq Listing Rule 5635(c)(4).

BioCryst Pharmaceuticals announced an exclusive license agreement with an Irish affiliate of Neopharmed Gentili to commercialize navenibart for hereditary angioedema (HAE) in Europe. BioCryst will receive $70 million upfront, with eligibility for up to $275 million in future regulatory and sales milestone payments, plus tiered royalties on net sales from 18% to 30%. This deal strengthens BioCryst's financial position and leverages an existing partnership, while the Phase 3 program for navenibart in HAE remains on track for a US regulatory filing by the end of 2027.